

CITATION REPORT

List of articles citing

AP-2 β regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription

DOI: 10.1038/emboj.2011.151
EMBO Journal, 2011, 30, 2569-81.

Source: <https://exaly.com/paper-pdf/51034541/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
132	Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. 2013 , 7, 370		47
131	Pioneer transcription factors: establishing competence for gene expression. 2011 , 25, 2227-41		1071
130	Context-specific regulation of NF- κ B target gene expression by EZH2 in breast cancers. 2011 , 43, 798-810		264
129	Pioneer factors: directing transcriptional regulators within the chromatin environment. 2011 , 27, 465-74		120
128	A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. <i>EMBO Journal</i> , 2012 , 31, 2810-23	13	116
127	Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. 2012 , 32, 399-414		125
126	Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A). 2012 , 32, 1633-44		49
125	Cistrome plasticity and mechanisms of cistrome reprogramming. 2012 , 11, 3199-210		6
124	Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. 2012 , 13, R88		53
123	Chromatin landscape and endocrine response in breast cancer. 2012 , 4, 675-83		12
122	Pioneer factors in hormone-dependent cancers. 2012 , 12, 381-5		180
121	Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. 2012 , 3, 147-59		28
120	Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells. 2012 , 103, 806-12		24
119	Tamoxifen resistance: from bench to bedside. 2013 , 717, 47-57		66
118	A tripartite transcription factor network regulates primordial germ cell specification in mice. 2013 , 15, 905-15		187
117	Genome-wide analysis uncovers high frequency, strong differential chromosomal interactions and their associated epigenetic patterns in E2-mediated gene regulation. 2013 , 14, 70		27
116	Cooperating transcription factors mediate the function of estrogen receptor. 2013 , 122, 1-12		12

115	Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. 2013 , 3, 342-9	251
114	Long-range transcriptional regulation of breast cancer genes. 2013 , 52, 113-25	5
113	A 914-bp promoter is sufficient to reproduce the endogenous prolyl oligopeptidase gene localization in the mouse placenta if not subject to position effect. 2013 , 524, 114-23	4
112	Estrogen receptor alpha: molecular mechanisms and emerging insights. 2013 , 114, 2203-8	9
111	Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor. 2013 , 20, 2204-12	18
110	Forkhead box proteins: tuning forks for transcriptional harmony. 2013 , 13, 482-95	417
109	FOXP1 and estrogen signaling in breast cancer. 2013 , 93, 203-12	16
108	A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. 2013 , 41, 8926-42	35
107	Deciphering cis-regulatory control in inflammatory cells. 2013 , 368, 20120370	13
106	Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. 2013 , 110, E1490-9	120
105	Approaches for assessing and discovering protein interactions in cancer. 2013 , 11, 1295-302	7
104	Towards an understanding of cell-specific functions of signal-dependent transcription factors. 2013 , 51, T37-50	24
103	Estrogen represses gene expression through reconfiguring chromatin structures. 2013 , 41, 8061-71	13
102	Co-regulated gene expression by oestrogen receptor and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. 2013 , 41, 10228-40	37
101	Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer. 2013 , 73, 6632-41	71
100	Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer. 2013 , 32, 4043-51	40
99	Amplitude modulation of androgen signaling by c-MYC. 2013 , 27, 734-48	62
98	Androgen receptor co-regulatory networks in castration-resistant prostate cancer. 2014 , 21, R1-R11	15

97	Genome-wide activity of unliganded estrogen receptor- β in breast cancer cells. 2014 , 111, 4892-7	64
96	Tissue-specific pioneer factors associate with androgen receptor cistromes and transcription programs. <i>EMBO Journal</i> , 2014 , 33, 312-26	13 82
95	Establishment of active chromatin structure at enhancer elements by mixed-lineage leukemia 1 to initiate estrogen-dependent gene expression. 2014 , 42, 2245-56	16
94	Complex formation and function of estrogen receptor β in transcription requires RIP140. 2014 , 74, 5469-79	21
93	Nucleosome eviction and multiple co-factor binding predict estrogen-receptor-alpha-associated long-range interactions. 2014 , 42, 6935-44	9
92	Large-scale quality analysis of published ChIP-seq data. 2014 , 4, 209-23	90
91	Estrogen receptor-mediated long-range chromatin interactions and transcription in breast cancer. 2014 , 382, 624-632	25
90	Hormone-regulated transcriptomes: lessons learned from estrogen signaling pathways in breast cancer cells. 2014 , 382, 652-664	67
89	Sumoylation pathway is required to maintain the basal breast cancer subtype. 2014 , 25, 748-61	63
88	Fast screening of ligand-protein interactions based on ligand-induced protein stabilization of gold nanoparticles. 2014 , 86, 2361-70	19
87	Hybrid assembly of DNA-coated gold nanoparticles with water soluble conjugated polymers for studying protein-DNA interaction and ligand inhibition. 2014 , 4, 8883	11
86	Transient estrogen receptor binding and p300 redistribution support a squelching mechanism for estradiol-repressed genes. 2014 , 28, 1522-33	50
85	Enhancer activation requires trans-recruitment of a mega transcription factor complex. 2014 , 159, 358-73	135
84	Studying forkhead box protein A1-DNA interaction and ligand inhibition using gold nanoparticles, electrophoretic mobility shift assay, and fluorescence anisotropy. 2014 , 448, 95-104	6
83	Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling. 2014 , 382, 633-641	41
82	Dynamic estrogen receptor interactomes control estrogen-responsive trefoil Factor (TFF) locus cell-specific activities. 2014 , 34, 2418-36	15
81	WDR5 Expression Is Prognostic of Breast Cancer Outcome. 2015 , 10, e0124964	31
80	3CPET: finding co-factor complexes from ChIA-PET data using a hierarchical Dirichlet process. 2015 , 16, 288	14

79	TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. 2015 , 34, 436-44	45
78	Lagging-strand replication shapes the mutational landscape of the genome. 2015 , 518, 502-506	156
77	Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling. 2015 , 36, 357-84	79
76	TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis. 2015 , 152, 519-31	24
75	TNF β signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome. 2015 , 58, 21-34	96
74	Androgen receptor- and PIAS1-regulated gene programs in molecular apocrine breast cancer cells. 2015 , 414, 91-8	8
73	The histone variant H2A.Z is an important regulator of enhancer activity. 2015 , 43, 9742-56	52
72	The Hierarchy of Transcriptional Activation: From Enhancer to Promoter. 2015 , 31, 696-708	93
71	Histone Posttranslational Modifications in Breast Cancer and Their Use in Clinical Diagnosis and Prognosis. 2016 , 467-477	
70	Epigenetic Alterations in Endocrine-Dependent Cancers: Implications of Endocrine Dysfunctions. 2016 , 351-374	
69	Inducible super-enhancers are organized based on canonical signal-specific transcription factor binding elements. 2017 , 45, 3693-3706	36
68	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. 2016 , 22, 5755-5764	11
67	Role of Estrogen Response Element in the Human Prolactin Gene: Transcriptional Response and Timing. 2016 , 30, 189-200	5
66	Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. 2016 , 76, 3989-4001	17
65	The Estrogen Receptor β Cistrome Beyond Breast Cancer. 2016 , 30, 1046-1058	18
64	Determination of DNA Binding Behavior of FoxA1 Constructs Using a Gold Nanoparticle-Based High Throughput Assay. 2016 , 04, 1640012	
63	The first decade of estrogen receptor cistromics in breast cancer. 2016 , 229, R43-56	13
62	Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. 2016 , 175, R41-9	48

61	SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. 2016 , 22, 479-91		13
60	iRegNet3D: three-dimensional integrated regulatory network for the genomic analysis of coding and non-coding disease mutations. 2017 , 18, 10		8
59	Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. 2017 , 114, E4482-E4491		64
58	Enhancers and chromatin structures: regulatory hubs in gene expression and diseases. 2017 , 37,		39
57	Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications. 2017 , 97, 1045-1087		183
56	The role of sex hormones and steroid receptors on female reproductive cancers. 2017 , 118, 93-108		80
55	In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus. 2017 , 45, 208-215		4
54	Dissecting the genomic activity of a transcriptional regulator by the integrative analysis of omics data. <i>Scientific Reports</i> , 2017 , 7, 8564	4-9	3
53	Fundamental Pathways in Breast Cancer 3: Estrogen Biology. 2017 , 19-26		
52	Reprimo, a Potential p53-Dependent Tumor Suppressor Gene, Is Frequently Hypermethylated in Estrogen Receptor Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6-3	3
51	Genome-Wide Association between Transcription Factor Expression and Chromatin Accessibility Reveals Regulators of Chromatin Accessibility. 2017 , 13, e1005311		17
50	Novel insights into chromosomal conformations in cancer. 2017 , 16, 173		21
49	TAD-free analysis of architectural proteins and insulators. 2018 , 46, e27		11
48	Signaling pathways and steroid receptors modulating estrogen receptor function in breast cancer. 2018 , 32, 1141-1154		60
47	Fluorescence sensing of protein-DNA interactions using conjugated polymers and graphene oxide. 2018 , 271, 97-103		12
46	Identification of a Wells-Dawson polyoxometalate-based AP-2 inhibitor with pro-apoptotic activity. 2018 , 475, 1965-1977		4
45	Novel lncRNA Regulates Prostate Cancer Cell Migration and Invasion through AR Signaling. 2018 , 16, 1865-1878		59
44	Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. <i>Nature Communications</i> , 2018 , 9, 3212	17.4	50

43	Dismissal of RNA Polymerase II Underlies a Large Ligand-Induced Enhancer Decommissioning Program. 2018 , 71, 526-539.e8		11
42	A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes. <i>Nature Communications</i> , 2018 , 9, 2311	17.4	63
41	Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer. 2019 , 29, 1429-1441		13
40	Identification of CHIP-seq and RIME grade antibodies for Estrogen Receptor alpha. 2019 , 14, e0215340		2
39	Classification of different types of estrogen receptor alpha binding sites in MCF-7 cells. 2019 , 299, 13-20		3
38	Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ER α function. 2019 , 9, 6501-6516		16
37	Repression of transcription factor AP-2 alpha by PPAR γ reveals a novel transcriptional circuit in basal-squamous bladder cancer. 2019 , 8, 69		11
36	A Gene Signature Is Predictive of Outcome in HER2-Positive Breast Cancer. 2020 , 18, 46-56		9
35	Estrogen Receptor-Mediated Gene Transcription and Cistrome. <i>Cancer Drug Discovery and Development</i> , 2019 , 49-70	0.3	1
34	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. 2020 , 38, 534-550.e9		19
33	Low-Dose Bisphenol A in a Rat Model of Endometrial Cancer: A CLARITY-BPA Study. 2020 , 128, 127005		2
32	Estrogen induces dynamic ER α and RING1B recruitment to control gene and enhancer activities in luminal breast cancer. <i>Science Advances</i> , 2020 , 6, eaaz7249	14.3	12
31	Alternatively Constructed Estrogen Receptor Alpha-Driven Super-Enhancers Result in Similar Gene Expression in Breast and Endometrial Cell Lines. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
30	Interaction of transcription factor AP-2 gamma with proto-oncogene PELP1 promotes tumorigenesis by enhancing RET signaling. <i>Molecular Oncology</i> , 2021 , 15, 1146-1161	7.9	8
29	Histone demethylase JMJD2B/KDM4B regulates transcriptional program via distinctive epigenetic targets and protein interactors for the maintenance of trophoblast stem cells. <i>Scientific Reports</i> , 2021 , 11, 884	4.9	4
28	Genome-wide estrogen receptor α chromatin binding in human colon cancer cells reveals its tumor suppressor activity. <i>International Journal of Cancer</i> , 2021 , 149, 692-706	7.5	3
27	Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer. <i>Molecular Aspects of Medicine</i> , 2021 , 78, 100939	16.7	2
26	Systematic dissection of transcriptional regulatory networks by genome-scale and single-cell CRISPR screens. <i>Science Advances</i> , 2021 , 7,	14.3	4

25	Estrogen-Receptor-Positive Breast Cancer in Postmenopausal Women: The Role of Body Composition and Physical Exercise. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	2
24	The Estrogen-Regulated Transcriptome: Rapid, Robust, Extensive, and Transient. <i>Cancer Drug Discovery and Development</i> , 2019 , 95-127	0.3	3
23	RUNX1 prevents oestrogen-mediated AXIN1 suppression and β -catenin activation in ER-positive breast cancer. <i>Nature Communications</i> , 2016 , 7, 10751	17.4	42
22	Mechanistic analysis of enhancer sequences in the Estrogen Receptor transcriptional program.		2
21	Nucleophosmin/B23 is a negative regulator of estrogen receptor β expression via AP2 in endometrial cancer cells. <i>Oncotarget</i> , 2016 , 7, 60038-60052	3.3	15
20	Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients. <i>Oncotarget</i> , 2016 , 7, 26465-79	3.3	17
19	Optimized CHIP-seq method facilitates transcription factor profiling in human tumors. <i>Life Science Alliance</i> , 2019 , 2, e201800115	5.8	28
18	The Contributions of RET Noncoding Variation to Hirschsprung Disease. 2012 , 169-194		
17	Feedback Regulation between Initiation and Maturation Networks Orchestrates the Chromatin Dynamics of Epidermal Lineage Commitment.		1
16	Estrogen-independent molecular actions of mutant estrogen receptor alpha in endometrial cancer.		1
15	Repression of Transcription Factor AP-2 Alpha by Peroxisome Proliferator Activated Receptor Gamma Reveals a Novel Transcriptional Circuit in basal-squamous Bladder Cancer.		
14	RET in breast cancer: pathogenic implications and mechanisms of drug resistance.. 2019 , 2, 1136-1152		2
13	Hdac3, Setdb1, and Kap1 mark H3K9me3/H3K14ac bivalent regions in young and aged liver.		
12	Nuclear role for human Argonaute-1 as an estrogen-dependent transcription coactivator. <i>Journal of Cell Biology</i> , 2020 , 219,	7.3	1
11	Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1.		
10	TFAP2 paralogs pioneer chromatin access for MITF and directly inhibit genes associated with cell migration.		0
9	A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.		
8	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.. <i>Frontiers in Immunology</i> , 2021 , 12, 800928	8.4	2

7	A Functional Network Model of the Metastasis Suppressor PEBP1/RKIP and Its Regulators in Breast Cancer Cells. <i>Cancers</i> , 2021 , 13,	6.6	1
6	TFAP2 paralogs facilitate chromatin access for MITF at pigmentation and cell proliferation genes.. <i>PLoS Genetics</i> , 2022 , 18, e1010207	6	0
5	High Levels of Progesterone Receptor B in MCF-7 Cells Enable Radical Anti-Tumoral and Anti-Estrogenic Effect of Progestin. 2022 , 10, 1860		
4	A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.		1
3	Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer. 2022 , 171-194		0
2	Roles of activator protein-2 gamma in breast cancer: A narrative review (SANRA). 2022 , 101, e30587		0
1	Hedgehog signaling activates a mammalian heterochronic gene regulatory network controlling differentiation timing across lineages. 2022 , 57, 2181-2203.e9		0